Revisiting Ipriflavone: a Potential Isoflavone for the Management of Postmenopausal Osteoporosis
- 13 October 2021
- journal article
- review article
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 31 (6) , 733-740
Abstract
No abstract availableKeywords
Funding Information
- Nitte (N/RG/NUFR2/ NGSMIPS /2020/01)
- Vision Group on Science and Technology (1003)
This publication has 42 references indexed in Scilit:
- Preventive effects of phytoestrogens against postmenopausal osteoporosis as compared to the available therapeutic choices: An overviewJournal of Natural Science, Biology and Medicine, 2011
- Zoledronate in the treatment of postmenopausal osteoporosisExperimental and Clinical Endocrinology & Diabetes, 2007
- Effect of Ipriflavone on Osteoblasts and Osteoclasts during Guided Bone AugmentationJournal of Health Science, 2007
- Equol, a natural estrogenic metabolite from soy isoflavonesBioorganic & Medicinal Chemistry, 2004
- Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to ratsLife Sciences, 2002
- PHARMACOKINETICS OF IPRIFLAVONE AND METABOLITES AFTER ORAL ADMINISTRATION OF A CORN-OIL SUSPENSION RELATIVEAmerican Journal of Therapeutics, 1997
- Bone density changes in postmenopausal women with the administration of ipriflavone alone or in association with low-dose ERTGynecological Endocrinology, 1997
- Ipriflavone, an Antiostheophorotic AgentActa Crystallographica Section C Crystal Structure Communications, 1996
- Inhibitory effect of ipriflavone on osteoclast-mediated bone resorption and new osteoclast formation in long-term cultures of mouse unfractionated bone cellsCalcified Tissue International, 1993
- Effects of ipriflavone and its metabolites on a clonal osteoblastic cell lineJournal of Bone and Mineral Research, 1991